Table 4.

Estimate of the annual economic burden of nosocomial S. aureus bloodstream infection in South Korea

		MRSA			MSSA
		Additional cost per patient ($)	Annual number of patients	Additional annual cost ($)	Additional cost per patient ($)	Annual number of patients	Additional annual cost ($)
Medical cost, median
Survivors		11,259	2003	22,551,777	4,797	847	4,063,059
Non survivors		14,772	943	13,929,996	408	139	56,712
Sub-total			2946	36,481,773		986	4,119,771
Cost of care giving						986
Survivors		927	2003	1,857,327	818	847	693,000
Non survivors		273	943	257,182	0*	139
Subtotal			2946	2,114,509		986	693,000
Productivity loss due to extended hospitalization
Survivors	Male	187	1368	255,546	165	425	70,051
	Female	126	635	80,163	111	421	46,895
Non survivors	Male	55	601	33,020	0*	59
	Female	37	342	12,698	0*	80
Subtotal			2946	381,428		986	116,946
Productivity loss due to premature death			943	21,397,796		139	1,887,336
Total additional cost of nosocomial SA-BSI			2946	60,375,506		986	6,817,053

Abbreviations: MRSA Methicillin-resistant S. aureus, MSSA Methicillin-susceptible S. aureus, SA-BSI S. aureus bloodstream infection.

*Because hospital stays were shorter in the non-survivors in the MSSA group, no additional cost was generated.